PT  - JOURNAL ARTICLE
AU  - Buckley, Rita
ED  - Bavbek, Sevil E.
TI  - Compassionate Use with CbzP Plus Prednisone for mCRPC: Interim Results
DP  - 2012 Jul 01
TA  - MD Conference Express
PG  - NP--NP
VI  - 12
IP  - 7
4099  - http://mdc.sagepub.com/content/12/7/NP.5.short
4100  - http://mdc.sagepub.com/content/12/7/NP.5.full
AB  - The XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer [TROPIC; NCT00417079] trial showed that treatment with cabazitaxel (CbzP) produced statistically significant improvement in overall survival versus mitoxantrone plus prednisone in patients with metastatic, castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen (HR, 0.70; p<0.0001). This article discusses interim results from a cohort compassionate-use program with CbzP plus prednisone for patients with mCRPC [EAP; NCT01254279; Bavbek SE et al. J Clin Oncol (suppl; asbtr e15112) 2012].